Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs

Arthritis Care and Research

Volumn 49, Issue 4, 2003, Pages 508-518

  Ofman, Joshua J ^a,f   Maclean, Catherine H ^b,c   Straus, Walter L ^d   Morton, Sally C ^c   Berger, Marc L ^d   Roth, Elizabeth A ^c   Shekelle, Paul G ^b,e  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Zynx Health   (United States)

Author keywords

Adverse events; Dyspepsia; Meta analysis; NSAIDs

Indexed keywords

ACEMETACIN; ANTRAFENINE; CARPROFEN; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENBUFEN; FENOPROFEN; FLOCTAFENINE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; ISOXICAM; KETOPROFEN; LORNOXICAM; MECLOFENAMIC ACID; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXYPHENBUTAZONE; PHENYLBUTAZONE; PIROXICAM; PIRPROFEN; PROGLUMETACIN; SALSALATE; SULINDAC; SUPROFEN; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESEARCH; DYSPEPSIA; EVALUATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 0042567437     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11192     Document Type: Article

References (185)

1. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-96.
2. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:447-59.
3. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
4. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
5. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9.
6. Soll AN, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19.
7. Chalmers TC, Berrier J, Hewitt P, Berlin J, Reitman D, Nagalingam R, et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1988;2 Suppl 1:9-26.
8. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
9. Garcia RL. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997;26:16-20.
10. Henry D, Lim LL, Garcia RL, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
11. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? A review and meta-analysis. J Clin Gastroenterol 1993;17:238-43.
12. Jadad AR, Moore RA, Carroll D, McQuay H. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
14. Data on File. IMS America. Westport, CT.
15. Barbara L, Camilleri M, Corinaldesi R, Crean GP, Heading RC, Johnson AG, et al. Definition and investigation of dyspepsia: consensus of an international ad hoc working party. Dig Dis Sci 1989;34:1272-6.
16. Talley NJ, Colin-Jones D, Koch KL. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-60.
17. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998;114:582-95.
18. Ioannidis JP, Cappelleri JC, Lau J, Nyren O, Sonnenberg A, Holtmann G. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med 1995;122:856-66.
19. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
20. Struck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993;342:1032-6.
21. Orwin RG. A fail-safe n for effect size in meta-analysis. J Educ Stat 1983;8:157-9.
22. Amlie E, Weber H, Holme I. Treatment of acute low-back pain with piroxicam: results of a double-blind placebo-controlled trial. Spine 1987;12:473-6.
23. Astrom M, Westlin N. No effect of piroxicam on achilles tendinopathy: a randomized study of 70 patients. Acta Orthop Scand 1992;63:631-4.
24. Balogh Z, Papazoglou SN, MacLeod M, Buchanan WW. A crossover clinical trial of piroxicam, indomethacin and ibuprofen in rheumatoid arthritis. Curr Med Res Opin 1979;6:148-53.
25. Berkowitz SS, Bernhard G, Bilka PJ, Blechman WJ, Marchesano JM, Rosenthal M, et al. Tolmetin versus placebo for the treatment of rheumatoid arthritis: a sequential double-blind clinical trial. Curr Ther Res 1974;16:442.
26. Berry H, Bird HA, Black C, Blake DR, Freeman AM, Golding DN, et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 1992;51:238-42.
27. Berry H, Bloom B, Fernandes L, Morris M. Comparison of timegadine and naproxen in rheumatoid arthritis: a placebo controlled trial. Clin Rheumatol 1983;2:357-61.
28. Berry H, Bloom B, Hamilton EBD. A comparative study of piroxicam (Feldene), diclofenac and placebo in osteoarthritis. Clin Trials J 1982;19:349-58.
29. Berry H, Coquelin JP, Gordon A, Seymour D. Antrafenine, naproxen and placebo in osteoarthritis: a comparative study. Br J Rheumatol 1983;22:89-94.
30. Bobrove AM, Calin A. Efficacy and tolerance of a novel precision-dose formulation of indomethacin: double-blind trials in rheumatoid arthritis and osteoarthritis. Curr Med Res Opin 1983;8 Suppl 2:55-61.
31. Boeckstyns MEH, Backer M, Petersen EM, Hoj I, Albrechtsen H, Andersen HB. Piroxicam spares buprenorphine after total joint replacement: controlled study of pain treatment in 81 patients. Acta Orthop Scand 1992;63:658-60.
32. Boeyinga JK, Callewaert JAM. Tiaprofenic acid (Surgam) in arthritic conditions: a randomized double-blind comparison with placebo in a multi-centre trial. Tijdschr Ther Geneesm Onderz 1984;9:492-6.
33. Bono RF, Finkel S, Goodman HF. Oxaprozin in the treatment of patients with tendinitis and bursitis: comparison with phenylbutazone and placebo. Semin Arthritis Rheum 1986;15 Suppl 2:90-4.
34. Brackertz B, Busson M. Comparative study of sulindac (Clinoril) and ibuprofen (Brufen) in osteoarthrosis. Br J Clin Pract 1978;32:77-80.
35. Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long term studies. J Am Geriatr Soc 1976;24:440-6.
36. Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal injury and gastroduodenal mucossal prostaglandins. Gastroenterology 1990;99:1616-21.
37. De Blecourt, JJ, Oh BK, Bernaert A. Tiaprofenic acid (Surgam): a double-blind crossover trial. Tijdschr Geneemiddelenonderz 1982;7:1434-7.
38. Dore R, Ballard I, Constantine G, McDonald P. Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Clin Ther 1995;17:656-66.
39. Ebel DL, Rhymer AR, Stahl E, Tipping R. Effect of clinoril (sulindac, msd), piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hypertension. Scand J Rheumatol 1986;15 Suppl 62:41-9.
40. El-Mehairy MM, Shaker A, Bahgat NE, Hamza S, Salam MS. A double blind comparison of niflumic acid with phenylbutazone, oxyphenylbutazone and placebo in the treatment of osteoarthrosis. Rheumatol Rehabil 1974;13:198-203.
41. Fasching U. Wirkungsvergleich von diflunisal, ibuprofen und plazebo bei der chronischen polyarthritis. [Diflunisal vs ibuprofen in rheumatoid arthritis.] Wien Klin Wochenschr 1983;95:869-72.
42. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7.
43. Hossain MA, Akbar FA, Thompson M. Floctafenine (Idarac) in the management of rheumatoid arthritis. Rheumatol Rehabil 1977;16:260-4.
44. Hutson MA. A double-blind study comparing ibuprofen 1800 mg or 2400 mg daily and placebo in sports injuries. J Int Med Res 86;14:142-7.
45. Jacob GB, Hart KK, Mullane JF. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr Ther Res 1983;33:703-13.
46. Kolarz G, Liem KS, Reichel H, Scherak O. Doppelblindstudie zwischein indometacin und cloximat, einem neuen nichtsteroid alen antirheumatikum. [Double blind comparison of indometacin and cloximate, a new nonsteroid antirheumatic agent.] Therapiewoche 1979;29:5898-902.
47. Kragballe K, Herlin T. Benoxaprofen improves psoriasis: a double-blind study. Arch Dermatol 1983;119:548-52.
48. Lacey PH, Dodd GD, Shannon DJ. A double blind, placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. Eur J Rheumatol Inflamm 1984;7:95-104.
49. Lanza FL, Nelson RS, Rack MF. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers. J Clin Pharmacol 1984;24:89-95.
50. Lanza FL, Rack MF, Royer GL. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normal volunteers: a comparative study. Clin Trials J 1986;23:168-77.
51. Lanza FL, Umbenhauer ER, Nelson RS, Rack MF, Daurio CP, White LA. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumatol 1982;9:415-9.
52. Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissila M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
53. Lussier A, Tetreault L, Lebel E. Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo. Am J Med 1983;75:80-3.
54. Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. Am J Gastroenterol 1992;87:996-1000.
55. Moore RA, McQuay HI, Carroll D, McMahon C, Allen MC. Single and multiple dose analgesic and kinetic studies of mefenamic acid in chronic back pain. Clin J Pain 1986;2:29-36.
56. Patoia L, Clausi G, Farroni F, Alberti P, Fugiani P, Bufalino L. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclo-dextrin, piroxicam and placebo administration. Eur J Clin Pharmacol 1989;36:599-604.
57. Perez JH, Masso RM, Imizcoz BJL. Meclofenamate sodium in the treatment of post-traumatic edema: report of a controlled double-blind study. Arzneim Forsch Drug Res 1983;33:663-7.
58. Petrick TJ, Black ME. Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada. Arzneim Forsch Drug Res 1983;33:631-5.
59. Petrick TJ, Bovenkerk WE. Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee: double-blind comparison with placebo and long-term experience. Arzneim Forsch Drug Res 1983;33:644-8.
60. Prupas HM, Loose LD, Spindler JS, Dietz AJ Jr, Gum OB, Weisman MH, et al. Tenidap in patients with rheumatoid arthritis: a 4-week, placebo-controlled study. Scand J Rheumatol 1996;25:345-51.
61. Ronen S, Rozenman Y, Zylbermann R, Berson D. Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery. Ann Ophthalmol 1985;17:577-81.
62. Rosekrans PCM, Stoyanova M, Mak M, Cats A, Steiner JF. A comparative study of sulindac (MK 231), aspirin and placebo in coxarthritis: some problems related to the clinical evaluation of analgesic, anti inflammatory drugs. Pharmatherapeutica 1976;1:52-64.
63. Royer GL, Seckman CE, Schwartz JH, Bennett KP. Effects of ibuprofen on normal subjects clinical and routine and special laboratory assessments. Curr Ther Res 1985;37:412-26.
64. Sanchez JL, Yanez MG. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease: report of a placebo-controlled double-blind clinical comparison. Arzneim Forsch Drug Res 1983;33:653-6.
65. Schnitzer TJ, Ballard IM, Constantine G, McDonald P. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Ther 1995;17:602-12.
66. Stadler P, Armstrong D, Margalith D, Saraga E, Stolte M, Lualdi P, et al. Diclofenac delays healing of gastroduodenal mucosal lesions: double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci 1991;36:594-600.
67. Thillainayagam AV, Tabaqchali S, Warrington SJ, Farthing MJ. Interrelationships between helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease: a prospective study in healthy volunteers. Dig Dis Sci 1994;39:1085-9.
68. Thompson M, Daymond TJ, Essigman WK, Huskisson EC, Wojtulewski JA. Short-term efficacy and tolerance of tiaprofenic acid (Surgam) in rheumatoid arthritis and osteoarthritis: multicentre placebo-controlled trials. Curr Med Res Opin 1982;8:215-23.
69. Van Der Kleijn E, Zelvelder WG. Diflunisal: a placebo-controlled trial. Tijdschr Geneesmiddelenonderz 1982;7:1345-51.
70. Van Der Pas HFM, Vertommen F. A double-blind study of naproxen-suppositories for post episitomial pain compared with ASA, oxyfenbutazon and placebo. Ars Med 1984;39:79-81.
71. Vargas FS, Esposito MA, Terra FM, et al. Naproxen sodico no tratamento dos processos infecciosos bronquicos. [Naproxen sodium in the treatment of bronchitic infectious processes.] Rev Bras Med 1983;40:144-8.
72. Weaver A, Rubin B, Caldwell J, McMahon FG, Lee D, Makarowski W, et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther 1995;17:735-45.
73. Weintraub M, Jacox RF, Angevine CD, Atwater EC. Piroxicam (CP 16171) in rheumatoid arthritis: a controlled clinical trial with novel assessment techniques. J Rheumatol 1977;4:393-404.
74. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304-10.
75. Williams P, Williams P, Currie WJC, VandenBurg MJ. A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis. Curr Med Res Opin 1983;8 Suppl 2:90-8.
76. Alcazar LFV, de Buergo M, Rico Lenza H, Montull Fruitos D. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. J Rheumatol 1996;23:1194-9.
77. Allen B, Edwards IR. A safety profile of controlled release naproxen tablets. N Z Med J 1989;102:310-2.
78. Andrade D, Gutierrez-Mendez G, Garcia-Miranda R. Ankle sprain clinical evolution after potassium diclofenac and sodium naproxen treatment. Folha Med 1985;90:83-8.
79. Aoki T, Kuroki Y, Kageyama T, Irimajiri S, Mizushima Y, Yamamoto K. Multicentre double-blind comparison of piroxicam and indomethacin in the treatment of lumbar diseases. Eur J Rheumatol Inflamm 83;6:247-52.
80. Appelrouth DJ, Chodock AL, Miller JL, Powell WR. A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1986;15 Suppl 2:54-8.
81. The Manchester General Practitioner Group. A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. Curr Med Res Opin 1984;9:41-6.
82. Balthazar-Letawe D, Cleppe D, Coigne E, DeCrans L, Dhondte E, Franchimont P, et al. Single daily dose of diclofenac retard tablets for the treatment of osteo-arthritis: a double-blind comparison with piroxicam: a multicenter study. Acta Ther 1984;10:413-20.
83. Batlle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. J Rheumatol 1996;23:1200-6.
84. Behrens U, Dumpert HP, Thummler W, Vetter G. A double-blind multicenter comparison of isoxicam and diclofenac in the treatment of osteoarthritis. Curr Ther Res 1985;37:739-46.
85. Bellamy N, Bensen WG, Beaulieu A, Simonovitch KA, Kraag GR, Lussier A, et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995;22:915-20.
86. Bennett RM. A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis. Clin Ther 1986;9 Suppl C:27-36.
87. Beveridge K. Treatment of sports injuries with naproxen sodium and dextropropoxyphene napsylate. Pharmatherapeutica 1985;4:393-8.
88. Bianchi-Porro G, Caruso I, Perrillo M. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med 1991;229:5-8.
89. Bianchi-Porro G, Montrone F, Petrillo M, Caruso I, Imbesi V. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995;90:1485-8.
90. Brown BL, Johnson JH, Hearron MS. Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis. Am J Med 1986;80:112-7.
91. Castles JJ, Moore TL, Vaughan JH, Bolzan JA, Lee M, Lidsky MD, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med 1978;138:362-6.
92. Cherie-Ligniere G, Colamussi V, Cozzolongo AC, Loizzi P, Frizziero L, Mattara L, et al. A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients. J Int Med Res 1983;11:85-9.
93. Colberg K, Hettich M, Sigmund R, Degner FL. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenacin patients with acute lumbago. Cur Med Res Opin 1995;13:363-77.
94. Cornhill J, Rowley-Jones D. Is sustained-release ibuprofen as effective as piroxicam: a comparison in patients with osteoarthritis. Eur J Rheumatol Inflamm 1984;7:114-21.
95. Currie WJC, Vandenburg MJ, Janke PG. Diggins JB. Symptomatic osteoarthritis in the elderly: multicentre comparative study of sulindac and ibuprofen. Br J Clin Pract 1984;38:176-81.
96. Diamond H, Alexander S, Kuzell W, Lussier A, Odone D, Tompkins R. Naproxen and aspirin in rheumatoid arthritis: a multicenter double blind crossover comparison study. J Clin Pharmacol 1975;15:335-9.
97. Dreiser RL. A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis. Rheumatol Int 1993;13 Suppl 2:S13-8.
98. Eberl R. A double-blind multicenter study comparing isoxicam and indomethacin in the treatment of degenerative joint disease. Semin Arthritis Rheum 1982;12 Suppl 2:175-8.
99. Ebner W, Poal BJM, Boussina I. Meclofenamate sodium in the treatment of ankylosing spondylitis: report of a European double-blind controlled multicenter study. Arzneim Forsch Drug Res 1983;33:660-3.
100. Edwards V, Wilson AA, Harwood HF, Manning SI, Brabbin W, Walker JW, et al. A multicentre comparison of piroxicam and indomethacin in acute soft tissue sports injuries. J Int Med Res 1984;12:46-50.
101. Eversmeyer W, Poland M, DeLapp RE, Jensen CP. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993;95:10S-18.
102. Famaey JP, Ginsberg F. Treatment of periarthritis of the shoulder: a comparison of ibuprofen and diclofenac. J Int Med Res 1984;12:238-43.
103. Fellmann N, Stocker H, Reuteler H. Double-blind study of suprofen vs naproxen in the treatment of osteoarthritic pain. Eur J Rheumatol Inflamm 1983;6:216-21.
104. Fiszman P, Perpetuo JBR, Sidi A. Ro 12-0068 (tenoxicam) in the treatment of extra-articular inflammatory processes. Eur J Rheumatol Inflamm 1985;8:15-20.
105. Furberg BL, Lerner A, Nystrom B, Rosen M, Willig P. Antiphlogistics in acute inflammatory conditions in the soft tissues of the musculo-skeletal system: a double blind comparison of diclofenac and indomethacin. Curr Ther Res 1985;38:523-7.
106. Garcia-Losa M. Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Med Clin (Barc) 1997;109:130-4.
107. Gomes JAM, Roth SH, Zeeh J, Bruyn GA, Woods EM, Geis GS. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52:881-5.
108. Gotte S, Homma W, Vallee P, Wittenborg A. Treatment of arthritis with controlled-release anti-inflammatory drugs. Fortschr Med 1986;104:567-70.
109. Herland OB, Husby G, Giercksky K-E, Holme I, Rugstad HE. Piroxicam and naproxen in osteoarthritis: a double-blind, comparative multicentre trial carried out in general practice. Tidsskr Nor Laegeforen 1986;106:2487-92, 2559.
110. Hosie J, Distel M, Bluhmki E. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study. Clin Drug Invest 1997;13:175-84.
111. Husby G, Holme I, Rugstad HE, Herland OB, Giercksky KE. A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clin Rheumatol 1986;5:84-91.
112. Janke PG, Diggins JB, Currie WJC, Dasgupta PK, Glick EN, Sheikh NA, et al. A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients. Pharmatherapeutica 1984;3:663-7.
113. Jessop JD, Evans DP. European double-blind multicenter study comparing isoxicam and indomethacin in treatment of degenerative joint disease. Am J Med 1985;79:24-7.
114. Karbowski A. Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. Cur Med Res Opin 1991;12:309-17.
115. Khan MA, Agarwal A, Cheatum D, Chubick A, Crane K, Fleischmann R, et al. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol 1987;14:118-23.
116. Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996;23:1605-11.
117. Kirchheiner B, Holm P, Jensen EM, Kryger J, Romberg O, Savelson A. A new long-acting anti-inflammatory agent, tenoxicam (Tilcotil) in osteoarthritis of the knee and the hip: a randomized comparison with indomethacin. Curr Ther Res 1982;32:627-32.
118. Knusel O. Double-blind comparative clinical trial of carprofen versus diclofenac-Na in patients with coxarthrosis. Eur J Rheumatol Inflamm 1982;5:536-42.
119. Kornasoff D, Frerick H, Bowdler J, Montull E. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 1997;16;32-8.
120. Kraag GR, Lussier A, Tetreault LL. Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis: a Canadian multi-center study. J Rheumatol 1985;12:328-36.
121. Lereim P, Gabor I. Piroxicam and naproxen in acute soft tissue disorders. Tidsskr Nor Laegeforen 1986;106:1021-3, 1055.
122. Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24 Suppl 47:10-6.
123. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35 Suppl 1:35-8.
124. Manz G. Pirprofen and indomethacin in patients with arthrosis: comparative double-blind study. Fortschr Med 85;103:176-8.
125. Manz G. Pirprofen und indometacin dei patienten mit arthrosen. [Pirprofen and indomethacin in patients with osteoarthritis.] Z Allgemeinmed 1984;60:820-3.
126. Marcolongo R, Giordano N, Mattara L, Leardini G, Lavezzari M, Gruni G, et al. A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritis. Eur J Rheumatol Inflamm 1983;6:201-8.
127. Meurice J. Treatment of osteoarthritis: a 3-month comparison between tiaprofenic acid and indomethacin. Curr Med Res Opin 1983;8:295-301.
128. Meyers OL, Quantock OP, Joubert PG, Louw DFDP, Marais DF, McDonald Scott WA, et al. A multicentre trial of Voltaren in the treatment of rheumatoid arthritis. S Afr Med J 1974;48:2013-7.
129. Mizushima Y, Shiokawa Y, Honma M, Kageyama T. A double-blind comparison of phenylbutazone and suxibuzone, a prodrug of phenylbutazone, in rheumatoid arthritis. Int J Tissue React 1983;5:35-9.
130. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993;95:19S-27S.
131. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl 1997;47:17-22.
132. Nichol FE, Daymond TJ, Pandit NA, Sheldon P, Swannell AJ. A controlled trial of tiaprofenic acid against indomethacin in patients with rheumatoid arthritis. Int J Clin Pharmacol Res 1985;5:157-9.
133. Noack W, Schneider H, Springorum H-W. Therapy of hip joint arthrosis with non-steroidal retard antirheumatics. Med Welt 1986;37:558-61.
134. Ohnishi M, Kawai T, Ogawa N. Double-blind evaluation of piroxicam and indomethacin in the treatment of inflammation following oral surgery. Eur J Rheumatol Inflamm 1983;6:259-65.
135. Orava S. Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. Int J Clin Pharmacol Res 1986;6:45-51.
136. Palferman TG, Struthers GR, Williams PI. Double-blind parallel comparison of etodolac and naproxen in patients with osteoarthritis of the knee. Acta Therapeutica 1991;17:19-34.
137. Perez BM, Calero E, Rodriguez M, Castellon Arce P, Bermudez A, Linares LF, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 1997;16:154-9.
138. Petera P, Tausch G, Eberl R. Doppelblindstudie mit tiaprofensaùre (surgam) gegen ibuprofen (brufen) bei patienten mit arthrosen der knie - und huftgelenke. [Double blind trial comparing tiaprofenic acid and ibuprofen in patients with osteoarthritis of the hips and the knees.] Wien Med Wochenschr 1983;133:409-12.
139. Pipitone V, Loizzi P, Casula PL, Bignamini AA. Double-blind clinical evaluation of a new anti-inflammatory drug, protacine, versus indomethacin. Curr Med Res Opin 1979;6:287-98.
140. Poiley JE, Spindler JS, Clarke JP, Brame CL. Nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis: a comparison of oxaprozin and ibuprofen. Semin Arthritis Rheum 1986;15 Suppl 2:59-65.
141. Porto A, Almeida H, Cunha MJ, Macciocchi A. Double-blind study evaluating by endoscopy the tolerability of nimesulide anal diclofenac on the gastric mucosa in osteoarthritic patients. Eur J Rheumatol Inflamm 1994;14:33-8.
142. Puhl W, Springorum HW. Konservative therapie der aktivierten gonarthrose: doppelblindstudie mit blindstudie mit proglumetacin und piroxicam. Proglumetacin versus piroxicam in activated gonarthrosis: a double-blind clinical investigation. Fortschr Med 1984;102:653-6.
143. Quattrini A, Paladin S. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthritis of the hip. Clin Drug Invest 1995;10:139-46.
144. Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. Scand J Rheumatol 1981;10 Suppl 36:1-7.
145. Rhymer AR, Sromovsky JA, Dicenta C, Hart CB. 'Osmosin': a multi-centre evaluation of a technological advance in the treatment of osteoarthritis. Curr Med Res Opin 1983;8 Suppl 2:62-71.
146. Rosenthal M. The efficacy of flurbiprofen versus piroxicam in the treatment of acute soft tissue rheumatism. Curr Med Res Opin 1984;9:304-9.
147. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
148. Roux H, Vignon G, Delcambre B, Simon L. Comparaison du pirprofene a 4 autres anti-inflammatoires non steroidiens dans le traitement de la polyarthrite rhumatoide. [Comparison of pirprofene with four other nonsteroid anti-inflammatory agents in the treatment of rheumatoid arthritis.] Rhumatologie (Lyon) 1983;35:113-7.
149. Royer GL, Moxley TE, Hearron MS, Miyara A, Donovan JF. A long term double blind clinical trial of ibuprofen and indomethacin in rheumatoid arthritis. J Int Med Res 1975;3:158-71.
150. Royer GL, Moxley TE, Hearron MS. A six month double blind trial of ibuprofen and indomethacin in osteoarthritis. Curr Ther Res 1975;17:234-48.
151. Salzman RT, Brobyn RD. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology 1983;27 Suppl 1:55-64.
152. Scharf Y, Nahir M, Schapira D, Lorber M. A comparative study of naproxen with diclofenac sodium in osteoarthrosis of the knees. Rheumatol Rehabil 1982;21:167-70.
153. Tannenbaum H, DeCoteau WE, Esdaile JM, Ryan JP, Fenton S, Markland J, et al. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr Ther Res 1984;36:426-35.
154. Turner RA, Whipple JP, Shackleford RW. Diflunisal 500-750 mg versus aspirin 2600-3900 mg in the treatment of rheumatoid arthritis. Pharmacotherapy 1984;4:151-7.
155. Uchida Y, Narita Y, Kushiro H. Clinical evaluation of CS-600 (loxoprofen sodium) on postexodontic pain: a multi-clinic double-blind study. J Oral Ther Pharmacol 1984;3:32-48.
156. Van Der Aa HE. A comparative trial of the analgesic effect of tiaprofenic acid and indomethacin in post-operative pain following spinal surgery in patients with radicular syndrome. Pharmatherapeutica 1984;4:43-7.
157. Wasner C, Britton MC, Kraines RG, Kraines RG, Kaye RL, Bobrove AM, et al. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981;246:2168-72.
158. Wietfeld K, Rubsamen B, Rechziegler H, Bernard I. Acemetacin and diclofenac treatment of patients with degenerative arthropathies. Med Welt 1986;37:1073-6.
159. Wojtulewski JA, Schattenkirchner M, Barcelo P, Le Loet X, Bevis PJ, Bluhmki E, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 1:22-8.
160. Yamamoto M, Sugano T, Kashiwazaki S, Kageyama T, Mizushima Y, Kameyama M. Double-blind comparison of piroxicam and indomethacin in the treatment of cervicobrachial syndrome and periarthritis scapulohumeralis (stiff shoulder). Eur J Rheumatol Inflamm 1983;6:266-73.
161. Benvenuti C, Beretta A, Longoni A, Pickvance NJ. A multicentre general practice study evaluating the efficacy and tolerance of ibuprofen in common painful conditions. Pharmatherapeutica 1984;4:9-12.
162. Bruni G, Lavezzari M, Perbellini A, Battaglia A, Emanueli A. Adverse reactions to indoprofen: a survey based on a total of 6764 patients. J Int Med Res 1982;10:306-24.
163. Busse V, Fischer I. Multicenter practical study of a sustained release formulation of diclofenac sodium in 4275 rheumatologic patients. Therapiewoche 1985;35:2336-41.
164. Cotillon C. Etude clinique de feldene 20 mg dans la polyarthritie rhumatoide. [Clinical trial of piroxicam in rheumatoid arthritis.] Gaz Med Fr 1984;91:131-5.
165. Daubresse AJ. Pirprofen for the treatment of rheumatic disorders and post-traumatic lesions. Acta Ther 1984;10:97-105.
166. Gerard MJ, Serrurier D. Pirprofene en rhumatologie etude chez 12217 malades. [Pirprofen in rheumatology: analysis of 12217 cases.] Rhumatologie (Lyon) 1983;35:293-7.
167. Gierend M, Grasedyck K, Lemmel E-M. Treatment of gonarthroses and coxarthroses: experience with a new dosage form of piroxicam. Munch Med Wochenschr 1985;127:90-7.
168. Harris PG. A monitored-release study of methrazone in general practice. J Int Med Res 1980;8:276-82.
169. Johnson JH, Jick H, Hunter JR, Dickson JF. A follow-up study of ibuprofen users. J Rheumatol 1985;12:549-52.
170. Jones CW. A post-marketing surveillance study of voltarol 75 mg SR in the primary care setting. Br J Clin Pract 1996;50:390-5.
171. Langloh N. Experience with piroxicam in general practice: results of a German multicenter study on 18,888 patients. Eur J Rheumatol Inflamm 1983;6:84-9.
172. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years: a large health maintenance organization cohort study. Arch Intern Med 1995;155:1371-7.
173. Martigny J. Efficacy and tolerance of feldene 20 mg in chronic rheumatism; study of 12926 patients. Gaz Med 1985;92:82-9.
174. Mason J, Bolton MS. A general practice assessment of Alrheumat (ketoprofen) in the treatment of rheumatic conditions. Br J Clin Pract 1977;31:127.
175. Mauser Th, Marx-Heep I, Adams HJ. Zur behandlung von erkrankungen des bewegungs: apparates mit tiaprofensaure. [Treatment of patients with arthritis and rheumatism with tiaprofenic acid: results of a multicenter study.] Therapiewoche 1984;34:3485-90.
176. Phelip X. La tolerance du Feldene (piroxicam): bilan de trois etudes cooperatives concernant 48353 observations. [Tolerance of piroxicam: analysis of 3 cooperative studies covering 48353 observations.] Gaz Med 1984;91:93-6.
177. Rawson NS. Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy. Ann Pharmacother 1995;29:676-80.
178. Rechziegler H, Von Bernuth K. Analgesic effect of acemetacin in rheumatic disease. Therapiewoche 1985;35:379-84.
179. Rostock D, Marx-Heep I, Adams H-J. Rheumatic disease treated with a new formulation of tiaprofenic acid. Therapiewoche 1985;35:5082-6.
180. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003.
181. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
182. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
183. Kay L, Jorgensen T. Epidemiology of upper dyspepsia in a random population: prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol 1994;29:2-6.
184. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62.
185. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.